Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation

Fig. 2

PD-L1 Expression in Non–Small-Cell Lung Cancers. Results were reported as the percentage of neoplastic cells showing membranous staining of programmed cell death ligand 1 (PD-L1) (proportion score). Shown are tumor samples obtained from patients with a proportion score of less than 1 % (Panel a), a score of 1 to 49 % (Panel b), and a score of at least 50 % (Panel c) (all at low magnification). Tumor samples with the corresponding proportion scores are shown at a higher magnification in Panels d through f. PD-L1 staining is shown by the presence of the brown chromogen. The blue color is the hematoxylin counterstain. From The New England Journal of Medicine, 2015, 372, 2018-2028 Edward B. Garon et al., Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer. Copyright © 2015 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society

Back to article page